A Randomized, Double-Blind, Placebo Controlled, Phase 2 Trial of Paclitaxel in Combination With AMG 386 in Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2018
At a glance
- Drugs Trebananib (Primary) ; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Amgen
- 24 Oct 2018 Planned End Date changed from 30 Nov 2018 to 17 Dec 2019.
- 31 Aug 2018 Biomarkers information updated
- 26 Mar 2018 Planned End Date changed from 29 Mar 2018 to 30 Nov 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History